<DOC>
	<DOCNO>NCT01989676</DOCNO>
	<brief_summary>The current study compare efficacy , safety , pharmacokinetics immunogenicity PF-05280014 combination paclitaxel versus trastuzumab source European Union ( trastuzumab-EU ) paclitaxel female patient HER2-positive , metastatic breast cancer first-line treatment setting . The hypothesis test study efficacy ( ORR ) PF-05280014 similar trastuzumab-EU .</brief_summary>
	<brief_title>A Study Of PF-05280014 Trastuzumab-Pfizer Or HerceptinÂ® Trastuzumab-EU Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment ( REFLECTIONS B327-02 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm diagnosis breast cancer . Presence metastatic disease . Documentation HER2 gene amplification overexpression . Available tumor tissue central review HER2 status . At least 1 measurable lesion define RECIST 1.1 . Eastern Cooperative Oncology Group status 0 2 . Left ventricular ejection fraction within institutional range normal , measure either two dimensional echocardiogram multigated acquisition scan . Relapse within 1 year last dose previous adjuvant ( include neoadjuvant ) treatment ( except endocrine therapy ) within 1 year randomization . Prior systemic therapy metastatic disease ( except endocrine therapy ) . Prior cumulative dose doxorubicin &gt; 400 mg/m2 , epirubicin dose &gt; 800 mg/m^2 , equivalent dose anthracyclines derivative ( eg , 72 mg/m^2 mitoxantrone ) . If patient receive one anthracycline , cumulative dose must exceed equivalent 400 mg/m^2 doxorubicin . Inflammatory breast cancer . Active uncontrolled symptomatic central nervous system metastasis .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase 3</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>Breast Neoplasms</keyword>
</DOC>